secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001104659-25-067940
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance appoints Corleen Roche as CFO effective August 6, 2025
--------------------------------------------------------------

- Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.
- Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.
- Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.
- Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/0001104659-25-067940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/tm2520947d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-067940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer